A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

This study compares two different chemotherapy approaches for adults and older teens newly diagnosed with moderate-to-high-risk acute myeloid leukemia (AML), a type of blood cancer. One approach uses a traditional chemotherapy regimen ("3+7") and the other uses a newer combination including a drug called venetoclax. **You may be eligible if...** - You are between 14 and 75 years old - You have been newly diagnosed with intermediate- or high-risk AML (not including a subtype called M3) - Your liver and kidney function are within acceptable levels - You do not have severe uncontrolled infections or major organ problems - You are in reasonably good physical health **You may NOT be eligible if...** - You are allergic to any of the study drugs - You are pregnant or breastfeeding - You have a history of alcohol or drug addiction - You have a mental illness that prevents following the treatment plan - You had major surgery in the past 6 weeks Talk to your doctor to see if this trial is right for you.